Ensysce Biosciences, Inc.

NASDAQ (USD): Ensysce Biosciences, Inc. (ENSC)

Last Price

0.579

Today's Change

-0.071 (10.92%)

Day's Change

0.541 - 0.74

Trading Volume

14,900,243

Overview

Market Cap

8 Million

Shares Outstanding

14 Million

Avg Volume

25,063,438

Avg Price (50 Days)

0.33

Avg Price (200 Days)

0.61

PE Ratio

-0.21

EPS

-2.70

Earnings Announcement

07-Nov-2024

Previous Close

0.65

Open

0.71

Day's Range

0.5406 - 0.74

Year Range

0.141 - 2.06

Trading Volume

15,109,656

Price Change Highlight

1 Day Change

-11.00%

5 Day Change

11.14%

1 Month Change

158.84%

3 Month Change

35.54%

6 Month Change

3.12%

Ytd Change

-47.88%

1 Year Change

-45.42%

3 Year Change

-99.89%

5 Year Change

-99.98%

10 Year Change

-99.70%

Max Change

-99.70%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment